These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 11575489)

  • 1. Optimal investment in a portfolio of HIV prevention programs.
    Zaric GS; Brandeau ML
    Med Decis Making; 2001; 21(5):391-408. PubMed ID: 11575489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users.
    Richter A; Brandeau ML; Owens DK
    Med Decis Making; 1999; 19(2):167-79. PubMed ID: 10231079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing HIV in injection drug users: choosing the best mix of interventions for the population.
    Wilson AR; Kahn JG
    J Urban Health; 2003 Sep; 80(3):465-81. PubMed ID: 12930884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A little planning goes a long way: multilevel allocation of HIV prevention resources.
    Zaric GS; Brandeau ML
    Med Decis Making; 2007; 27(1):71-81. PubMed ID: 17237455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Employing resource allocation modeling to inform HIV prevention planning for the state of Iowa.
    Holtgrave DR; Young PA; Mayer RR; Maulsby C; Kim JJ
    AIDS Educ Prev; 2013 Oct; 25(5):423-9. PubMed ID: 24059879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A linear programming model for allocating HIV prevention funds with state agencies: a pilot study.
    Earnshaw SR; Hicks K; Richter A; Honeycutt A
    Health Care Manag Sci; 2007 Sep; 10(3):239-52. PubMed ID: 17695135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model for allocating CDC's HIV prevention resources in the United States.
    Lasry A; Sansom SL; Hicks KA; Uzunangelov V
    Health Care Manag Sci; 2011 Mar; 14(1):115-24. PubMed ID: 21184183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Portfolio evaluation of health programs: a reply to Sendi et al.
    Bridges JF; Terris DD
    Soc Sci Med; 2004 May; 58(10):1849-51. PubMed ID: 15020002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allocating HIV prevention resources: a tool for state and local decision making.
    Richter A; Hicks KA; Earnshaw SR; Honeycutt AA
    Health Policy; 2008 Sep; 87(3):342-9. PubMed ID: 18342388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portfolio theory and cost-effectiveness analysis: a further discussion.
    Sendi P; Al MJ; Rutten FF
    Value Health; 2004; 7(5):595-601. PubMed ID: 15367254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
    Bernard CL; Owens DK; Goldhaber-Fiebert JD; Brandeau ML
    PLoS Med; 2017 May; 14(5):e1002312. PubMed ID: 28542184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV Treatment and Prevention: A Simple Model to Determine Optimal Investment.
    Juusola JL; Brandeau ML
    Med Decis Making; 2016 Apr; 36(3):391-409. PubMed ID: 26369347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allocating HIV prevention funds in the United States: recommendations from an optimization model.
    Lasry A; Sansom SL; Hicks KA; Uzunangelov V
    PLoS One; 2012; 7(6):e37545. PubMed ID: 22701571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules.
    O'Brien BJ; Sculpher MJ
    Med Care; 2000 May; 38(5):460-8. PubMed ID: 10800973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved allocation of HIV prevention resources: using information about prevention program production functions.
    Brandeau ML; Zaric GS; de Angelis V
    Health Care Manag Sci; 2005 Feb; 8(1):19-28. PubMed ID: 15782509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework.
    Bautista-Arredondo S; Gadsden P; Harris JE; Bertozzi SM
    AIDS; 2008 Jul; 22 Suppl 1():S67-74. PubMed ID: 18664956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations.
    Sendi P; Al MJ; Gafni A; Birch S
    Soc Sci Med; 2004 May; 58(10):1853-5. PubMed ID: 15020003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision-making in HIV prevention community planning: an integrative review.
    Johnson-Masotti AP; Pinkerton SD; Holtgrave DR; Valdiserri RO; Willingham M
    J Community Health; 2000 Apr; 25(2):95-112. PubMed ID: 10794204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.